Immunization Fact Sheet: Respiratory Syncytial Virus (RSV)



Topic Nirsevimab (Beyfortus[™]) Manufacturer AstraZeneca and Sanofi Product Info **Detailed prescribing information** use links **Respiratory Syncytial Virus (RSV) Protects Against Approved Ages** FDA Licensed for: Neonates and infants born during or entering their first RSV season. • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. **Routine Schedule** 1 dose for all infants <8 months born during or entering their 1st RSV season if: & Intervals The birth parent did not receive RSV vaccine during pregnancy. The birth parent's RSV vaccination status is unknown. The infant was born within 14 days of prenatal RSV vaccination. • 1 dose for infants and children 8–19 months old entering their 2nd RSV season and who are at increased risk for severe RSV: Native American/Alaska Native children • Children with chronic lung disease of prematurity who required medical • support (chronic corticosteroids, diuretics, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season. Children who are severely immunocompromised. Children with cystic fibrosis who have either: Severe lung disease (previous hospitalization for pulmonary 0 exacerbation in the first year of life or abnormalities on chest imaging that persist when stable). • Weight-for-length that is <10% percentile. Administration IM (intramuscular) injection. Packaging Pre-filled syringes: 50mg (0.5mL) with **purple** plunger rod (for infants weighing <5 kg) 100 mg (1mL) with light blue plunger rod Cartons of five pre-filled syringes: Five 50 mg/0.5 mL single-dose pre-filled syringes in a carton Five 100 mg/1 mL single-dose pre-filled syringes in a carton Packaging images available at: See packaging images Dosage Age <8 months: Weight <5 kg: 50 mg dose (purple plunger rod) • Weight ≥5 kg: 100 mg dose (**light blue** plunger rod) Age 8-19 months: 200 mg dose (2 separate 100 mg injections, at the same time at different sites)

Vaccine Fact Sheet: Respiratory Syncytial Virus (RSV) (Continued)

Торіс	Nirsevimab (Beyfortus [™])
Recommended Timing	 For infants born during RSV season: Within 1 week of birth. Infants with prolonged birth hospitalizations should receive nirsevimab shortly before or promptly after hospital discharge. For infants born outside of RSV season and children 8-19 months: Optimal administration is at the start of RSV season, usually October. Nirsevimab should be offered throughout the RSV season, typically October through March. For considerations of nirsevimab versus palivizumab for high-risk children, see: <u>Nirsevimab (Beyfortus) Timing Guide</u>
Shipping	Nirsevimab ships similarly to other pediatric routine vaccines.
Storage	Routine Storage: In a refrigerator at 2°C– 8°C; DO NOT FREEZE. Short-term storage: Room temperature (20°C – 25°C), for 8 hours, if protected from light.
Use-by Limit	Nirsevimab has a shelf life of about 18 months. Once removed from the refrigerator, must be used within 8 hours or discarded.
Expiration Date	See packaging for expiration info. Nirsevimab can be returned after expiration, similar to other Sanofi vaccine products. See more for details.
Full ACIP Recommendations	Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children MMWR
VIS	Information Immunization Statement
Program Letter	VFC Letter
Billing Codes	NDC Code(s): 49281-574-15, 49281-574-88, 49281-575-00, 49281-575-15 https://www.cdc.gov/vaccines/programs/iis/fall-season-respiratory-codes.html
Comments	Licensed in 2023

Refer to <u>Vaccine Fact Sheets</u> (EZIZ.org/Resources/VaccineFactSheets).